I see your point but in terms of the current ruling you would have to have overwhelming evidence during an appeal, during the trial I would agree with you.
On another note, do you think Hikma is working with Teva? I mean they can do a fake launch of the limited application using Teva as the supplier and Teva can produce the generic with no limitation of the expanded usage per the settlement.
This would be some next level strategy or Teva could have just boxed in Amarin and forced them to go to court with other generics knowing that it was a possibility for the patents to ruled as obvious in a limited sense. Thus, settling would give them the upper hand. Does anyone have the full settlement agreement?
Market Data 
Markets 
AI
